Benchmark Capital Advisors trimmed its stake in Pfizer (NYSE:PFE) by 9.6% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 100,075 shares of the biopharmaceutical company’s stock after selling 10,600 shares during the quarter. Pfizer accounts for 2.8% of Benchmark Capital Advisors’ portfolio, making the stock its 6th largest position. Benchmark Capital Advisors’ holdings in Pfizer were worth $3,625,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of the company. Americafirst Capital Management LLC acquired a new position in Pfizer in the third quarter worth approximately $127,000. Delphi Private Advisors LLC increased its holdings in Pfizer by 84.3% in the fourth quarter. Delphi Private Advisors LLC now owns 3,499 shares of the biopharmaceutical company’s stock worth $127,000 after buying an additional 1,600 shares during the last quarter. Lipe & Dalton increased its holdings in Pfizer by 6.9% in the second quarter. Lipe & Dalton now owns 4,626 shares of the biopharmaceutical company’s stock worth $155,000 after buying an additional 300 shares during the last quarter. Legacy Advisors LLC acquired a new position in Pfizer in the third quarter worth approximately $164,000. Finally, Oak Point Wealth Management acquired a new position in Pfizer in the fourth quarter worth approximately $165,000. 71.33% of the stock is owned by institutional investors and hedge funds.

A number of equities analysts recently commented on PFE shares. Morningstar set a $38.00 price objective on Pfizer and gave the stock a “neutral” rating in a report on Tuesday, January 30th. Barclays downgraded Pfizer from an “overweight” rating to an “equal weight” rating and dropped their price objective for the stock from $41.00 to $38.00 in a report on Thursday, April 5th. UBS set a $42.00 price objective on Pfizer and gave the stock a “buy” rating in a report on Wednesday, January 31st. Zacks Investment Research upgraded Pfizer from a “hold” rating to a “buy” rating and set a $41.00 price objective on the stock in a report on Wednesday, January 24th. Finally, Sanford C. Bernstein set a $43.00 price objective on Pfizer and gave the stock a “buy” rating in a report on Tuesday, January 30th. Two equities research analysts have rated the stock with a sell rating, twelve have issued a hold rating and nine have given a buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of $39.20.

Shares of PFE stock opened at $37.00 on Friday. Pfizer has a 12 month low of $31.67 and a 12 month high of $39.43. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.10 and a current ratio of 1.35. The company has a market cap of $218,351.08, a price-to-earnings ratio of 13.96, a P/E/G ratio of 1.83 and a beta of 0.90.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.62 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.56 by $0.06. The business had revenue of $13.70 billion for the quarter, compared to the consensus estimate of $13.67 billion. Pfizer had a net margin of 40.55% and a return on equity of 25.21%. Pfizer’s quarterly revenue was up .6% on a year-over-year basis. During the same quarter last year, the company posted $0.47 earnings per share. sell-side analysts anticipate that Pfizer will post 2.96 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 1st. Stockholders of record on Friday, May 11th will be paid a $0.34 dividend. This represents a $1.36 annualized dividend and a dividend yield of 3.68%. Pfizer’s payout ratio is 51.32%.

In other news, Director W Don Cornwell sold 1,758 shares of the firm’s stock in a transaction on Tuesday, February 27th. The shares were sold at an average price of $36.79, for a total value of $64,676.82. Following the sale, the director now owns 1,000 shares in the company, valued at $36,790. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Charles H. Hill sold 42,393 shares of the firm’s stock in a transaction on Tuesday, March 6th. The stock was sold at an average price of $35.76, for a total transaction of $1,515,973.68. The disclosure for this sale can be found here. In the last 90 days, insiders sold 248,037 shares of company stock worth $9,064,785. 0.06% of the stock is currently owned by corporate insiders.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.